News
Hong Kong biotechs IPOs face lower valuations after Ascletis...
Biotechs taking an advantage of new Hong Kong exchange rules have been told to expect lower valuations, after Chinese pioneer Ascletis Pharma’s shares plunged nearly 45% in the first month
